Các bài viết có thể truy cập công khai - Pierre FumoleauTìm hiểu thêm
Không có ở bất kỳ nơi nào: 1
522 Preclinical Evaluation of Indium 111 Radiolabeled Trastuzumab and Pertuzumab for HER2-positive Breast Cancer Molecular Imaging
A Oudot, B Collin, O Raguin, M Moreau, JM Vrigneaud, O Duchamp, ...
European Journal of Cancer 48, 161, 2012
Các cơ quan ủy nhiệm: Austrian Science Fund
Có tại một số nơi: 17
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic …
AC Wolff, AA Lazar, I Bondarenko, AM Garin, S Brincat, L Chow, Y Sun, ...
Journal of clinical oncology 31 (2), 195-202, 2013
Các cơ quan ủy nhiệm: US National Institutes of Health
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
S Ladoire, G Mignot, S Dabakuyo, L Arnould, L Apetoh, C Rébé, ...
The Journal of pathology 224 (3), 389-400, 2011
Các cơ quan ủy nhiệm: National Institute of Health and Medical Research, France
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
E Raymond, AA Brandes, C Dittrich, P Fumoleau, B Coudert, ...
Journal of Clinical Oncology 26 (28), 4659-4665, 2008
Các cơ quan ủy nhiệm: US National Institutes of Health
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and …
H Bonnefoi, S Litière, M Piccart, G MacGrogan, P Fumoleau, E Brain, ...
Annals of oncology 25 (6), 1128-1136, 2014
Các cơ quan ủy nhiệm: US National Institutes of Health, National Institute of Health and Medical …
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials
T Gorlia, R Stupp, AA Brandes, RR Rampling, P Fumoleau, C Dittrich, ...
European journal of cancer 48 (8), 1176-1184, 2012
Các cơ quan ủy nhiệm: US National Institutes of Health
Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer
J Gobbo, G Marcion, M Cordonnier, AMM Dias, N Pernet, A Hammann, ...
Journal of the National Cancer Institute 108 (3), djv330, 2016
Các cơ quan ủy nhiệm: Swiss Cancer League
Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy
S Ladoire, L Arnould, G Mignot, B Coudert, C Rébé, F Chalmin, J Vincent, ...
Breast cancer research and treatment 125, 65-72, 2011
Các cơ quan ủy nhiệm: National Institute of Health and Medical Research, France
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
H Bonnefoi, M Piccart, J Bogaerts, L Mauriac, P Fumoleau, E Brain, T Petit, ...
The lancet oncology 12 (6), 527-539, 2011
Các cơ quan ủy nhiệm: US National Institutes of Health
Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer
S Ladoire, F Penault-Llorca, L Senovilla, C Dalban, D Enot, C Locher, ...
Autophagy 11 (10), 1878-1890, 2015
Các cơ quan ủy nhiệm: European Commission, Swiss Cancer League
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France
JY Blay, S Boucher, B Le Vu, C Cropet, S Chabaud, D Perol, E Barranger, ...
ESMO open 6 (3), 100134, 2021
Các cơ quan ủy nhiệm: National Institute of Health and Medical Research, France, Agence Nationale …
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
J Braybrooke, R Bradley, R Gray, RK Hills, H Pan, R Peto, D Dodwell, ...
The Lancet 401 (10384), 1277-1292, 2023
Các cơ quan ủy nhiệm: US National Institutes of Health, Cancer Research UK, UK Medical Research …
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial
S Ladoire, G Mignot, C Dalban, A Chevriaux, L Arnould, C Rébé, ...
Annals of oncology 23 (10), 2552-2561, 2012
Các cơ quan ủy nhiệm: National Institute of Health and Medical Research, France
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients
DG Cox, E Curtit, G Romieu, P Fumoleau, M Rios, H Bonnefoi, T Bachelot, ...
Oncotarget 7 (47), 77358, 2016
Các cơ quan ủy nhiệm: Swiss Cancer League
A Phase I, dose-escalation trial of pazopanib in combination with cisplatin in patients with advanced solid tumors: A UNICANCER study
V Diéras, T Bachelot, M Campone, N Isambert, F Joly, C Le Tourneau, ...
Oncology and Therapy 4, 211-223, 2016
Các cơ quan ủy nhiệm: Swiss Cancer League
Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel+ trastuzumab-based neoadjuvant chemotherapy
E Schmitt, F Végran, S Chevrier, L Burillier, M Cadouot, S Lizard-Nacol, ...
BMC cancer 15, 1-6, 2015
Các cơ quan ủy nhiệm: Swiss Cancer League
Phase III trial (EORTC 10994/BIG 1-00) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus non taxane primary chemotherapy in breast …
H Bonnefoi, M Piccart, J Bogaerts, L Mauriac, P Fumoleau, E Brain, T Petit, ...
The Lancet. Oncology 12 (6), 527, 2011
Các cơ quan ủy nhiệm: US National Institutes of Health
Annals of Oncology Advance Access published March 11, 2014
H Bonnefoi, S Litière, M Piccart, G MacGrogan, P Fumoleau, E Brain, ...
Các cơ quan ủy nhiệm: US National Institutes of Health, National Institute of Health and Medical …
Chương trình máy tính sẽ tự động xác định thông tin xuất bản và thông tin về nhà tài trợ